In this context, it would be relevant to compare the levels of HER2 sialylation among the BC cell lines used, and test whether de-sialylation could improve the immune responsiveness to anti-HER2 blockade seen in the HCC1954-based model. This evidence concerns the gene ERBB2 and breast cancer.